Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Active, not recruiting · NCT05358639 · Registry updated 2024-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2024-11-18 | NCT05358639 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Centre hospitalier de l'Université de Montréal (CHUM) | 138 |
| Exactis Innovation | 2 |
| Princess Margaret Hospital, Canada | 28 |
| Sunnybrook Health Sciences Centre | 193 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHUM | Montreal | Canada | 11 |
| Princess Margaret Cancer Centre | Toronto | Canada | 14 |
| Sunnybrook Research Institute/Odette Cancer Centre | Toronto | Canada | 1 |